WeVote
Log In

Bill

Bill

S 6029

Requires the health equity council to issue mandates related to the treatment of sickle cell disease

2025 Regular Session Introduced by Kevin Parker

Requires Health Equity Council to issue mandates on SCD treatment, setting standards and affecting patients, providers, insurers, and state agencies.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · S 6029

Summary of S 6029

Quick overview

  • Bill number: S 6029
  • Title: Requires the health equity council to issue mandates related to the treatment of sickle cell disease
  • Status: REFERRED TO HEALTH
  • Introduced: March 4, 2025
  • Related bill: S 8924 (prior-session)

Purpose and intent

S 6029 would require the state’s Health Equity Council to issue mandates concerning the treatment of sickle cell disease (SCD). The aim, as indicated by the title, appears to be to establish formal requirements or standards related to how SCD is treated, with a focus on equity considerations. The summary provided does not specify the scope or nature of the mandates (e.g., clinical guidelines, coverage requirements, access assurances, or enforcement mechanisms).

Key provisions (as stated in available information)

  • A primary directive: The Health Equity Council shall issue mandates related to the treatment of sickle cell disease.
  • Other substantive provisions, scope details, timelines, enforcement, funding, and implementation specifics are not included in the available summary. The full text would be required to outline the exact mandates, eligible settings (e.g., clinical care, coverage, patient access), and any compliance requirements.

Who would be affected

  • Patients with sickle cell disease and their families, who could benefit from standardized or mandated treatment approaches.
  • Healthcare providers and care teams treating SCD.
  • Health insurers and health systems that would be subject to any mandates related to treatment.
  • The Health Equity Council, which would have new statutory duties to issue these mandates.
  • State health agencies or departments responsible for implementing or enforcing the mandates (if applicable).

Procedural and timeline aspects

  • Introduced on March 4, 2025.
  • Status indicates referral to the Health committee for consideration and potential action.
  • The legislative path beyond referral (e.g., hearings, amendments, floor votes) would depend on committee proceedings and subsequent floor action.
  • Related legislation (S 8924) from a prior session may indicate ongoing or evolving policy discussions around SCD treatment and health equity.

Potential impact and considerations

  • If enacted, the bill would shift authority to a state body (the Health Equity Council) to establish mandates governing SCD treatment, which could influence standards of care, access, or coverage depending on the final language.
  • The lack of detail in the summary means questions remain about scope, enforcement, funding, and implementation timelines.
  • Stakeholders may want to review the full text to assess fiscal implications, impact on clinical practice, and potential effects on insurers and patients.

Note: A complete, precise analysis requires the full bill text to identify specific mandates, definitions, timelines, and enforcement mechanisms.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.